JP2023501720A5 - - Google Patents

Info

Publication number
JP2023501720A5
JP2023501720A5 JP2022528256A JP2022528256A JP2023501720A5 JP 2023501720 A5 JP2023501720 A5 JP 2023501720A5 JP 2022528256 A JP2022528256 A JP 2022528256A JP 2022528256 A JP2022528256 A JP 2022528256A JP 2023501720 A5 JP2023501720 A5 JP 2023501720A5
Authority
JP
Japan
Prior art keywords
target
independently
drugs
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022528256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501720A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/061127 external-priority patent/WO2021102052A1/en
Publication of JP2023501720A publication Critical patent/JP2023501720A/ja
Publication of JP2023501720A5 publication Critical patent/JP2023501720A5/ja
Pending legal-status Critical Current

Links

JP2022528256A 2019-11-18 2020-11-18 指向性コンジュゲーション技術 Pending JP2023501720A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962937131P 2019-11-18 2019-11-18
US62/937,131 2019-11-18
US202063063902P 2020-08-10 2020-08-10
US63/063,902 2020-08-10
PCT/US2020/061127 WO2021102052A1 (en) 2019-11-18 2020-11-18 Directed conjugation technologies

Publications (2)

Publication Number Publication Date
JP2023501720A JP2023501720A (ja) 2023-01-18
JP2023501720A5 true JP2023501720A5 (enExample) 2023-11-24

Family

ID=75981011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528256A Pending JP2023501720A (ja) 2019-11-18 2020-11-18 指向性コンジュゲーション技術

Country Status (12)

Country Link
US (1) US20230128688A1 (enExample)
EP (1) EP4061425A4 (enExample)
JP (1) JP2023501720A (enExample)
KR (1) KR20220103986A (enExample)
CN (1) CN115066263A (enExample)
AU (1) AU2020388383A1 (enExample)
BR (1) BR112022009398A2 (enExample)
CA (1) CA3160681A1 (enExample)
IL (2) IL293095B2 (enExample)
MX (1) MX2022005884A (enExample)
PH (1) PH12022551000A1 (enExample)
WO (1) WO2021102052A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022078566A1 (en) * 2020-10-12 2022-04-21 Debiopharm Research & Manufacturing S.A. Reactive conjugates
BR112023023506A2 (pt) * 2021-05-17 2024-01-30 Biohaven Therapeutics Ltd Composições incluindo intensificadores de terapia conjugada
CA3219550A1 (en) * 2021-05-19 2022-11-24 Gene M. Dubowchik Antibody drug conjugates using mates technology for delivering cytotoxic agents
CN113636960A (zh) * 2021-08-24 2021-11-12 上海皓元医药股份有限公司 一种2-(氯磺酰基)环己烷-1-烯甲酸乙酯衍生物的制备方法
CN114085376B (zh) * 2021-12-02 2022-12-20 中国科学院长春应用化学研究所 一种多肽及其制备方法、双特异性抗体及其应用
WO2025158412A1 (en) 2024-01-26 2025-07-31 Biohaven Therapeutics Ltd. BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS
WO2025181697A1 (en) 2024-02-26 2025-09-04 Biohaven Therapeutics Ltd. Bifunctional degraders of anti-pla2r antibody
WO2025210538A1 (en) 2024-04-02 2025-10-09 Biohaven Therapeutics Ltd. Bifunctional degraders
WO2026028159A1 (en) 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Bifunctional degraders for the treatment of graves' disease
WO2026028158A1 (en) 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Targeted degradation of anti-aav antibodies to enable aav-based gene therapy
WO2026083257A1 (en) 2024-10-14 2026-04-23 Biohaven Therapeutics Ltd. Antigen-specific degraders of immunoglobulin a and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201407600UA (en) * 2012-06-19 2014-12-30 Polytherics Ltd Novel process for preparation of antibody conjugates and novel antibody conjugates
GB201506407D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
JP2019518017A (ja) * 2016-02-09 2019-06-27 アレクサンダー・クランツ トレースレス親和性標識を使用したタンパク質の部位選択的官能化
US11135307B2 (en) * 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
ES3066090T3 (en) * 2017-04-28 2026-05-11 Ajinomoto Co Inc Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
EP3658170A4 (en) * 2017-07-26 2021-08-25 Kleo Pharmaceuticals, Inc. UNIVERSAL ABT CONNECTIONS AND THEIR USES

Similar Documents

Publication Publication Date Title
JP2022532134A5 (enExample)
AU2017225111B2 (en) Modified antibody regions and uses thereof
TWI886164B (zh) 1價ccap生成物之製造方法
JP2002513795A (ja) モノマー、オリゴマーおよびポリマーのクネベナーゲル縮合生成物
JP2021508449A5 (enExample)
KR20220110209A (ko) 이중 il-2r 및 il-7r 결합 화합물
WO2023281484A1 (en) Synthetic il-7 and il-7 immunocytokines
CN111971060A (zh) 募集抗体并靶向肿瘤细胞的双功能分子
JP7605290B2 (ja) 化合物またはその塩、およびそれらにより得られる抗体
Kimmel et al. Solid-phase synthesis of megamolecules
JP2024521092A5 (enExample)
WO2023054714A1 (ja) 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
JP2021535108A5 (enExample)
AU2026202991A1 (en) Compound or salt thereof, and antibody produced using same
WO1994020521A1 (de) Verfahren zur synthese und selektionierung von sequenzen aus kovalent verbundenen bausteinen
WO2024210154A1 (ja) 抗体および機能性物質のコンジュゲート、抗体誘導体ならびに化合物、またはそれらの塩
TW202214307A (zh) 奈米脂蛋白－多肽結合物及組成物、系統及其使用方法
DE69423753T2 (de) Polyoximverbindungen und deren herstellung
JP7670072B2 (ja) 化合物またはその塩、およびそれらにより得られる抗体
PT1817342E (pt) Método de purificação por afinidade
CN118742329A (zh) 包含抗组织因子抗体-药物缀合物的药物组合物
JP2024519031A5 (enExample)
JP2024516392A5 (enExample)
US20240148877A1 (en) Synthetic Strategy to Polymerize Protein into Molecularly Defined Polymers
JP2012522021A (ja) 合成ペプチド及びその応用